Literature DB >> 22209743

Mapping for economic evaluation.

Ling-Hsiang Chuang1, Sarah J Whitehead.   

Abstract

INTRODUCTION/
BACKGROUND: Mapping provides a statistical algorithm that allows the estimation of utilities and consequently calculation of QALYs in clinical studies where preference-based measures are not implemented. SOURCES OF DATA: Reviews of the mapping literature were utilized. AREAS OF AGREEMENT: Mapping requires similar populations between the estimation and study data sets, with a high degree of overlap between the target and base measures being desirable. The National Institute for Health and Clinical Excellence recognizes mapping as a method to provide utility information. Areas of controversy Issues surrounding mapping include the descriptive system of the measure, the appropriate econometric method and model specification. GROWING POINTS: There is a need for further research into the issue of over-prediction for severe health states and uncertainty around the estimated utility scores. AREAS TIMELY FOR DEVELOPING RESEARCH: Mapping continues to be an important area of research for economic evaluation, in particular validation of mapping functions.

Mesh:

Year:  2011        PMID: 22209743     DOI: 10.1093/bmb/ldr049

Source DB:  PubMed          Journal:  Br Med Bull        ISSN: 0007-1420            Impact factor:   4.291


  20 in total

1.  The potential for a generally applicable mapping model between QLQ-C30 and SF-6D in patients with different cancers: a comparison of regression-based methods.

Authors:  Nick Kontodimopoulos
Journal:  Qual Life Res       Date:  2014-11-13       Impact factor: 4.147

2.  Mapping clinical outcomes to generic preference-based outcome measures: development and comparison of methods.

Authors:  Mónica Hernández Alava; Allan Wailoo; Stephen Pudney; Laura Gray; Andrea Manca
Journal:  Health Technol Assess       Date:  2020-06       Impact factor: 4.014

3.  Mapping CHU9D Utility Scores from the PedsQLTM 4.0 SF-15.

Authors:  Christine Mpundu-Kaambwa; Gang Chen; Remo Russo; Katherine Stevens; Karin Dam Petersen; Julie Ratcliffe
Journal:  Pharmacoeconomics       Date:  2017-04       Impact factor: 4.981

4.  Should linking replace regression when mapping from profile-based measures to preference-based measures?

Authors:  Peter M Fayers; Ron D Hays
Journal:  Value Health       Date:  2014-03       Impact factor: 5.725

5.  Can Mapping Algorithms Based on Raw Scores Overestimate QALYs Gained by Treatment? A Comparison of Mappings Between the Roland-Morris Disability Questionnaire and the EQ-5D-3L Based on Raw and Differenced Score Data.

Authors:  Jason Madan; Kamran A Khan; Stavros Petrou; Sarah E Lamb
Journal:  Pharmacoeconomics       Date:  2017-05       Impact factor: 4.981

Review 6.  The estimation of utility weights in cost-utility analysis for mental disorders: a systematic review.

Authors:  Michael Sonntag; Hans-Helmut König; Alexander Konnopka
Journal:  Pharmacoeconomics       Date:  2013-12       Impact factor: 4.981

7.  Mapping scores from the Strengths and Difficulties Questionnaire (SDQ) to preference-based utility values.

Authors:  Gareth Furber; Leonie Segal; Matthew Leach; Jane Cocks
Journal:  Qual Life Res       Date:  2013-08-13       Impact factor: 4.147

8.  The MAPS Reporting Statement for Studies Mapping onto Generic Preference-Based Outcome Measures: Explanation and Elaboration.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

9.  Preferred Reporting Items for Studies Mapping onto Preference-Based Outcome Measures: The MAPS Statement.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Pharmacoeconomics       Date:  2015-10       Impact factor: 4.981

10.  Preferred reporting items for studies mapping onto preference-based outcome measures: The MAPS statement.

Authors:  Stavros Petrou; Oliver Rivero-Arias; Helen Dakin; Louise Longworth; Mark Oppe; Robert Froud; Alastair Gray
Journal:  Health Qual Life Outcomes       Date:  2015-08-01       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.